Yearly Archives: 2012

­

Quark Pharmaceuticals Reports Favorable Interim Results from Phase I Clinical Study of QPI-1007

January 4th, 2012|

Fremont, CA January 4, 2012, — Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced interim results from the first two cohorts of its Open Label, first-in-human Phase I clinical study of QPI-1007, the Company‚Äôs proprietary synthetic siRNA drug candidate for ocular neuroprotection, in patients with recent onset […]